Randomized study of etirinotecan pegol versus irinotecan as second-line treatment for metastatic colorectal cancer.
Authors
Lenz, HPhilip, P
Saunders, Mark P
Kolevska, T
Mukherjee, K
Samuel, L
Bondarde, S
Dobbs, T
Tagliaferri, M
Hoch, U
Hannah, A
Berkowitz, M
Affiliation
USC Norris Comprehensive Cancer Center, 1441 Eastlake Ave Rm 3456, Los Angeles, CAIssue Date
2017-12
Metadata
Show full item recordAbstract
Etirinotecan pegol (EP) is a long-acting topoisomerase-I inhibitor designed to provide sustained exposure to SN-38 (active metabolite of irinotecan). This phase II study compared EP versus irinotecan as second-line treatment for KRAS-mutant, irinotecan-naïve, metastatic colorectal cancer (mCRC).Citation
Randomized study of etirinotecan pegol versus irinotecan as second-line treatment for metastatic colorectal cancer. 2017, 80(6): 1161-1169 Cancer Chemother PharmacolJournal
Cancer Chemotherapy and PharmacologyDOI
10.1007/s00280-017-3438-yPubMed ID
29043412Type
ArticleLanguage
enISSN
1432-0843ae974a485f413a2113503eed53cd6c53
10.1007/s00280-017-3438-y
Scopus Count
Collections
Related articles
- Randomized multicenter phase II trial comparing two schedules of etirinotecan pegol (NKTR-102) in women with recurrent platinum-resistant/refractory epithelial ovarian cancer.
- Authors: Vergote IB, Garcia A, Micha J, Pippitt C, Bendell J, Spitz D, Reed N, Dark G, Fracasso PM, Ibrahim EN, Armenio VA, Duska L, Poole C, Gennigens C, Dirix LY, Leung AC, Zhao C, Soufi-Mahjoubi R, Rustin G
- Issue date: 2013 Nov 10
- Etirinotecan pegol (NKTR-102) versus treatment of physician's choice in women with advanced breast cancer previously treated with an anthracycline, a taxane, and capecitabine (BEACON): a randomised, open-label, multicentre, phase 3 trial.
- Authors: Perez EA, Awada A, O'Shaughnessy J, Rugo HS, Twelves C, Im SA, Gómez-Pardo P, Schwartzberg LS, Diéras V, Yardley DA, Potter DA, Mailliez A, Moreno-Aspitia A, Ahn JS, Zhao C, Hoch U, Tagliaferri M, Hannah AL, Cortes J
- Issue date: 2015 Nov
- A multicenter, open-label, expanded phase 2 study to evaluate the safety and efficacy of etirinotecan pegol, a polymer conjugate of irinotecan, in women with recurrent platinum-resistant or refractory ovarian cancer.
- Authors: Rustin G, Vergote I, Micha JP, Duska LR, Reed N, Bendell J, Spitz D, Dark G, Hoch U, Tagliaferri M, Hannah AL, Garcia AA
- Issue date: 2017 Nov
- Etirinotecan Pegol (NKTR-102) in Third-line Treatment of Patients With Metastatic or Recurrent Non-Small-cell Lung Cancer: Results of a Phase II Study.
- Authors: Aggarwal C, Cohen RB, Yu E, Hwang WT, Bauml JM, Alley E, Evans TL, Langer CJ
- Issue date: 2018 Mar
- A multicenter, phase I, dose-escalation study to assess the safety, tolerability, and pharmacokinetics of etirinotecan pegol in patients with refractory solid tumors.
- Authors: Jameson GS, Hamm JT, Weiss GJ, Alemany C, Anthony S, Basche M, Ramanathan RK, Borad MJ, Tibes R, Cohn A, Hinshaw I, Jotte R, Rosen LS, Hoch U, Eldon MA, Medve R, Schroeder K, White E, Von Hoff DD
- Issue date: 2013 Jan 1